{"classes":[{"categories":[{"measurements":[{"comment":"N/A = Median not reached since no patients progressed","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A = Median not reached since too few no of patients with progressions (n=2)","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"Duration of angiomyolipoma response was defined as the time from the date of the first documented angiomyolipoma response until the date of the first documented angiomyolipoma progression . Angiomyolipoma response was defined as the combination of the following criteria: reduction in angiomyolipoma volume of ≥ 50% relative to baseline, where angiomyolipoma volume was sum of volumes of all target lesions identified at baseline, and with a confirmatory scan performed approximately 12 weeks later (no sooner than 8 weeks later); no new angiomyolipoma lesions ≥ 1.0 cm in longest diameter were identified; there were no kidney increases in volume \\> 20% from nadir. The patient did not have any angiomyolipoma-related bleeding of ≥ grade 2.","dispersionType":"95% Confidence Interval","groups":[{"description":"Study drug was given by continuous oral daily dosing of two 5 mg tablets.","id":"OG000","title":"Everolimus Randomized (Core Period)"},{"description":"Patients initially randomized in everolimus and patients initially randomized in placebo but who crossed-over to everolimus during extension.","id":"OG001","title":"Everolimus (Core and/or Extension Period)"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed on the Full analysis Set for patients in Everolimus arm and who experienced an angiomyolipoma response.","reportingStatus":"POSTED","timeFrame":"From date of randomization until the earliest date of first documented AML progression, date of further anti-AML medication (including open-label Everolimus)/surgery or up to about 5.7 years","title":"Duration of Angiomyolipoma Response - Only Everolimus Patients With Angiomyolipoma Response","type":"SECONDARY","unitOfMeasure":"months"}